Online inquiry

IVTScrip™ mRNA-Anti-CSF1R, FPA-008(Cap 0, Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ7295MR)

This product GTTS-WQ7295MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & Pseudo-UTP. It ecodes the monoclonal antibody that targets CSF1R gene. The antibody can be applied in Rheumatoid arthritis (RA) research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_001288705.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 1436
UniProt ID P07333
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CSF1R, FPA-008(Cap 0, Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ7295MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ10390MR IVTScrip™ mRNA-Anti-TNFSF13B, LY2127399(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA LY2127399
GTTS-WQ13131MR IVTScrip™ mRNA-Anti-APP, PF-04360365(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA PF-04360365
GTTS-WQ1511MR IVTScrip™ mRNA-Anti-INHBA, ACE-011(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA ACE-011
GTTS-WQ1162MR IVTScrip™ mRNA-Anti-VEGFA, ABP 215(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA ABP 215
GTTS-WQ7556MR IVTScrip™ mRNA-Anti-GPC3, GC33(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA GC33
GTTS-WQ1568MR IVTScrip™ mRNA-Anti-BMP10&GDF2, ACE-041(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA ACE-041
GTTS-WQ14303MR IVTScrip™ mRNA-Anti-ANGPT2&VEGFA, RG-7221(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA RG-7221
GTTS-WQ9634MR IVTScrip™ mRNA-Anti-PDCD1, JNJ-63723283(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA JNJ-63723283
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW